Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Local Administration of Recombinant Oncolytic Adenovirus Injection (KD01) in Patients With Gynecologic Malignancies

NCT06552598 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06552598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06552598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Local Administration of Recombinant Oncolytic Adenovirus Injection (KD01) in Patients With Gynecologic Malignancies
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
April 1, 2024
Completion date
April 1, 2028
Enrollment
97 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, gynecologic malignancies